Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat

British Journal of Pharmacology

Volumn 122, Issue 7, 1997, Pages 1523-1529

  Wegener, Jörg W ^a   Gath, Ingolf ^a   Förstermann, Ulrich ^a   Nawrath, Hermann ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Aortic smooth muscle; Cardiomyocytes; Cyclic GMP; Heart muscle; L type Ca2+ current; Tension

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 3 (5' HYDROXYMETHYL 2' FURYL)BENZYLINDAZOLE; ATRIOPEPTIN II; CALCIUM ION; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; INDAZOLE DERIVATIVE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; OXADIAZOLE DERIVATIVE; PHENYLEPHRINE; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HEART CONTRACTION; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE RELAXATION;

EID: 0030730472     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701542     Document Type: Article

References (36)

1. BEAVO, J.A. (1988). Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv. Second Messenger Phosphoprotein Res., 22, 1-38.
2. 2+-dependent potassium channels in vascular smooth muscle. Nature, 368, 850-853.
3. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
4. BRADY, A.J., WARREN, J.B., POOLE-WILSON, P.A., WILLIAMS, T.J. & HARDING, S.E. (1993). Nitric oxide attenuates cardiac myocyte contraction. Am. J. Physiol., 265, H176-H182.
5. BRUNNER, F., SCHMIDT, K., NIELSEN, E.B. & MAYER, B. (1996). Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J. Pharmacol. Exp. Ther., 277, 48-53.
6. CELLEK, S., KASAKOV, L. & MONCADA, S. (1996). Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. Br. J. Pharmacol., 118, 137-140.
7. FRIEBE, A., SCHULTZ, G. & KOESLING, D. (1996). Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J., 15, 6863-6868.
8. GARTHWAITE, J., SOUTHAM, E., BOULTON, C.L., NIELSON, E.B., SCHMIDT, K. & MAYER, B. (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol., 48, 184-188.
9. GRUETTER, C.A., GRUETTER, D.Y., LYON, J.E., KADOWITZ, P.J. & IGNARRO, L.J. (1981). Relationship between cyclic guanosine 3′:5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J. Pharmacol. Exp. Ther., 219, 181-186.
10. HAMILL, O.P., MARTY, A., NEHER, E., SAKMANN, B. & SIGWORTH, F.J. (1981). Improved patch-clamp techniques for high resolution current recording from cells and cell free membrane patches. Pflügers Arch., 391, 85-100.
11. HARE, J.M. & COLUCCI, W.S. (1995). Role of nitric oxide in the regulation of myocardial function. Prog. Cardiovasc. Dis., 38, 155-166.
12. HEBEISS, K. & KILBINGER, H. (1996). Differential effects of nitric oxide donors on basal and electrically evoked release of acetylcholine from guinea-pig myenteric neurones. Br. J. Pharmacol., 118, 2073-2078.
13. IGNARRO, L.J. (1990). Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol., 30, 535-560.
14. KELLY, R.A., BALLIGAND, J.L. & SMITH, T.W. (1996). Nitric oxide and cardiac function. Circ. Res., 79, 363-380.
15. KO, F.N., WU, C.C., KUO, S.C., LEE, F.Y. & TENG, C.M. (1994). YC-1, a novel activator of platelet guanylate cyclase. Blood, 84, 4226-4233.
16. KOJDA, G., BRIXIUS, K., KOTTENBERG, K., NIX, P., SCHLUTER, K.D., PIPER, H.M. & NOACK, E. (1995). The new NO donor SPM3672 increases cGMP and improves contraction in rat cardiomyocytes and isolated heart. Eur. J. Pharmacol., 284, 315-319.
17. KOJDA, G., KOTTENBERG, K., NIX, P., SCHLUTER, K.D., PIPER, H.M. & NOACK, E. (1996). Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ. Res., 78, 91-101.
18. KONTOS, H.A. & WEI, E.P. (1993). Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke, 24, 427-434.
19. LUGNIER, C., SCHOEFFTER, P., LE-BEC, A., STROUTHOU, E. & STOCLET, J.C. (1986). Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol., 35, 1743-1751.
20. MAYER, B., BRUNNER, F. & SCHMIDT, K. (1993). Inhibition of nitric oxide synthesis by methylene blue. Biochem. Pharmacol., 45, 367-374.
21. MCCALL, D. & FRIED, T.A. (1990). Effect of atriopeptin II on Ca influx, contractile behavior and cyclic nucleotide content of cultured neonatal rat myocardial cells. J. Mol. Cell. Cardiol., 22, 201-212.
22. MORO, M.A., RUSSEL, R.J., CELLEK, S., LIZASOAIN, I., SU, Y., DARLEY-USMAR, V.M., RADOMSKI, M.W. & MONCADA, S. (1996). Cyclic GMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U.S.A., 93, 1480-1485.
23. MÜLSCH, A., BAUERSACHS, J., SCHÄFER, A., STASCH, J.P., KAST, R. & BUSSE, R. (1997). Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol., 120, 681-689.
24. MÜLSCH, A., BUSSE, R., LIEBAU, S. & FÖRSTERMANN, U. (1988). LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J. Pharmacol. Exp. Ther., 247, 283-288.
25. MURAD, F. (1994). Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv. Pharmacol., 26, 19-33.
26. NAWRATH, H., BÄUMNER, D., RUPP, J. & OELERT, H. (1995). The ineffectiveness of the NO-cyclic GMP signalling pathway in the atrial myocardium. Br. J. Pharmacol., 116, 3061-3067.
27. SMITH, J.A., SHAH, A.M. & LEWIS, M.J. (1991). Factors released from endocardium of the ferret and pig modulate myocardial contraction. J. Physiol., 439, 1-14.
28. STAMLER, J.S., SINGEL, D.J. & LOSCALZO, J. (1992). Biochemistry of nitric oxide and its redox-activated forms. Science, 258, 1898-1902.
29. ++-dependent constitutive nitric oxide synthase is not involved in the cyclic GMP-increasing effects of carbachol in ventricular cardiomyocytes. J. Pharmacol. Exp. Ther., 266, 919-925.
30. STEINER, A.L., PARKER, C.W. & KIPNIS, D.M. (1972). Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J. Biol. Chem., 247, 1106-1113.
31. WEGENER, J.W. & NAWRATH, H. (1995). Extracellular site of action of phenylalkylamines on L-type calcium current in rat ventricular myocytes. Naunyn Schmiedeberg's Arch. Pharmacol., 352, 322-330.
32. WEGENER, J.W. & NAWRATH, H. (1997). Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur. J. Pharmacol., 323, 89-91.
33. WEYRICH, A.S., MA, X.L., BUERKE, M., MUROHARA, T., ARMSTEAD, V.E., LEFER, A.M., NICOLAS, J.M., THOMAS, A.P., LEFER, D.J. & VINTEN-JOHANSEN, J. (1994). Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated cardiac muscle. Circ. Res., 75, 692-700.
34. WU, C.C., KO, F.N., KUO, S.C., LEE, F.Y. & TENG, C.M. (1995). YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol., 116, 1973-1978.
35. YU, S.M. & KUO, S.C. (1995). Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylyl cyclase activator, in rat aorta. Br. J. Pharmacol., 114, 1587-1594.
36. ZHUO, M., HU, Y., SCHULTZ, C., KANDEL, E.R. & HAWKINS, R.D. (1994). Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature, 368, 635-639.